A specialty pharma company whose value is recognized globally
First written in FY2016. 25 of 27 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Our group has defined its long-term vision as “growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.”」
There has been no significant change to the long-term vision, which continues to serve as a premise for the 25-27 Medium-Term Management Plan. - FY2026-H1RestatedAnnual report
「Our group (the Company and its consolidated subsidiaries, hereinafter the same) has adopted the long-term vision of “growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.”」
The long-term vision of becoming a distinctive life and health-related corporate group whose value is recognized globally is reaffirmed. - FY2025RestatedAnnual report
「Our group has defined its long-term vision as “growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.”」
The long-term vision of being a distinctive life and health-related corporate group whose value is recognized globally continues. - FY2025-H1RestatedAnnual report
「Our group (the Company and its consolidated subsidiaries, hereinafter the same) is consolidating the collective capabilities of the Group from research and development through manufacturing and sales, pursuing selective concentration to achieve sustainable growth, and restructuring its earnings structure to respond to further changes in the operating environment, with the aim of growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.」
The long-term business vision of becoming a distinctive life and health-related corporate group whose value is recognized globally continues to be presented. - FY2023RestatedAnnual report
「Our group has defined its long-term vision as “growing as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.”」
The long-term vision of becoming a distinctive life and health-related corporate group whose value is recognized globally is reaffirmed. - FY2022RestatedAnnual report
「We will grow as a distinctive life and health-related corporate group whose value is recognized globally by addressing medical and healthcare needs.」
The long-term vision of being a distinctive life and health-related corporate group is reaffirmed with respect to the long-term business vision, including the previous specialty pharma concept. - FY2022-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products.」
No significant change has been indicated in the business vision of becoming a specialty pharma company through a focus on priority areas and activities centered on key products. - FY2021ReframedAnnual report
「We aim to become a distinctive life and health-related corporate group whose value is recognized globally, centered on our pharmaceutical business and including our healthcare business and new fields related to these business areas.」
The wording of the business vision has changed from the previous “specialty pharma company whose value is recognized globally” to “a distinctive life and health-related corporate group.” - FY2021-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2021-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information centered on key products is reaffirmed. - FY2021-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2020RestatedAnnual report
「The 持田製薬 Group will continue to pursue sustainable growth in corporate value as a specialty pharma company whose value is recognized globally, while maximizing its strengths, including the mobility and agility of a mid-sized company, as a life and health-related corporate group.」
The long-term business vision of becoming a specialty pharma company whose value is recognized globally is reaffirmed. - FY2020-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information centered on key products is reaffirmed. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2019RestatedAnnual report
「The 持田製薬 Group will continue to pursue sustainable growth in corporate value as a specialty pharma company whose value is recognized globally, while maximizing its strengths, including the mobility and agility of a mid-sized company, as a comprehensive health-related corporate group.」
The long-term business vision of becoming a specialty pharma company whose value is recognized globally is reaffirmed. - FY2019-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information centered on key products is reaffirmed. - FY2019-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2019-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, psychiatry and gastroenterology, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2018RestatedAnnual report
「The 持田製薬 Group will continue to pursue sustainable growth in corporate value as a specialty pharma company whose value is recognized globally, while maximizing its strengths, including the mobility and agility of a mid-sized company, as a comprehensive health-related corporate group.」
The long-term business vision of becoming a specialty pharma company whose value is recognized globally is reaffirmed. - FY2018-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
We continue to pursue the business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information. - FY2018-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2018-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, among others, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reaffirmed. - FY2017-Q3RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reiterated. - FY2017-Q2RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The policy of becoming a specialty pharma company through a focus on priority areas and the provision of scientific information is reiterated. - FY2017-Q1RestatedAnnual report
「In the pharmaceutical-related business, we concentrated resources in the priority areas of cardiovascular medicine, obstetrics and gynaecology, dermatology, emergency medicine and psychiatry, and actively conducted medical information activities centered on our core products with the aim of becoming a specialty pharmaceutical company.」
The business vision of becoming a specialty pharma company is reiterated together with the focus on priority areas and the provision of scientific information. - FY2016First statedAnnual report
「Over the long term, we will invest in business activities linked to our future competitiveness, including building the next generation of growth drivers, with the aim of becoming a specialty pharma company whose value is recognized globally.」
The long-term business vision and investment policy are presented together.